Sandoz to supply critical generic injectable meds
The pharma maker is partnering with the nonprofit Civica Rx to help reduce shortages in hospitals.
Sandoz will supply critical injectable generic medicines to hospitals to “help reduce supply shortages and ensure acute care settings can deliver optimal patient care,” the pharma maker said in a press release.
Sandoz entered into a five-year agreement with Civica Rx, a non-profit committed to making quality generic medicines available and affordable to its 1,200 hospital members.
Related: Generic EpiPen for kids may help with shortage
Sandoz will supply six injectable medicines widely used at Civica’s U.S.member hospitals — currently in higher demand due to COVID-19. They include antibiotics, acid reducers, blood thinners, blood pressure regulators, and medicines required in the operating room.
“Frequent supply shortages of critical generic medicines result in additional pressure for hospitals and their staff and often lead to sub-optimal patient care. Our partnership with Civica is delivering on a shared purpose to help ensure patient access to critical, high-quality medicines for years to come,” said Carol Lynch, president of Sandoz.
“Our associates are inspired every day to deliver on this purpose, even more so during this time of increased demand due to the global healthcare crisis,” Lynch added.
Related: U.S. accuses generic drug makers of price collusion
The manufacturer will start shipping the medications to Civica later this year.
Seventy percent of hospital pharmacy managers said in a 2018 survey that, on at least 50 occasions in the prior year, they were unable to provide hospitals with medicines needed to treat their patients because of shortages, Sandoz said.
Read more: GAO: Generic drug approvals too slow
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Trelegy and Breo Offer Incremental Improvement Over Generics
March 3rd 2025The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat patients with chronic obstructive pulmonary disease that are part of CMS's drug price negotiation program.
Read More
